Most read articles by the same author(s)
- Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto, The future of Funds for Innovative Medicines: results from a Delphi Study , Global and Regional Health Technology Assessment: Vol. 8 No. 1 (2021): January-December 2021
- Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi, The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study , Global and Regional Health Technology Assessment: Vol. 9 No. 1 (2022): January-December 2022
- Carla Rognoni, Arianna Bertolani, Claudio Jommi, Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018